Purpose: We aimed to compare the effectiveness of intranasal desmopressin and doxazosin treatments in patients with nocturia and benign prostatic hyperplasia (BPH).
Material And Methods: Thirty one men with BPH and three or more episodes of nocturia were randomized to receive 2 mg doxazosin at night for two weeks increasing to 4 mg for a further two weeks versus 20 μg intranasal desmopressin at night. For all patients, number of nocturia, urinary flow rate, residual urine volume and quality of life score were checked. Outcomes were measured at two months. The comparison of before and after treatment changes between the groups were done by student's t-test.
Results: In doxazosin group, mean number of nocturia were 3.2 &plus mn; 0.4 (3-4 times) times per night and 1.2 +/- 0.8 (0-3 times) times per night before and after treatment, respectively. In desmopressin group, mean number of nocturia were 3.4 +/- 0.5 (3-4 times) and 1.5 +/- 0.6 (1-3 times) times per night before and after treatment, respectively. In doxazosin group, mean residual urine volumes were 44.3 +/- 35.9 ml (range 0-120 ml) and 23.1 +/- 18.8 ml (range 0-50 ml) before and after treatment, respectively. In desmopressin group, mean residual urine volumes were 36.6 +/- 32.4 ml (range 0-120 ml) and 14.0 +/- 26.9 ml (range 0-90 ml) before and after treatment, respectively. Improvements in number of nocturia, residual urine volume, quality of life scores and peak urinary flow rates weren't statistically significant between two groups, whereas change in international prostate symptom score (IPSS) score was more significant in doxazosin group.
Conclusion: Intranasal desmopressin, is an effective symptomatic treatment of men with BPH complaining of nocturia, as well as doxazosin treatment.
Download full-text PDF |
Source |
---|
J Rhinol
March 2024
Department of Otolaryngology-Head and Neck Surgery, Bucheon Saint Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Background And Objectives: This study aimed to determine the efficacy of prophylactic desmopressin administered via the intranasal or intravenous route in reducing intraoperative bleeding during nasal surgery. We conducted a meta-analysis of the relevant literature to investigate the role of preoperative desmopressin in minimizing bleeding complications associated with nasal surgery.
Methods: We screened the relevant literature published before February 2023.
Int J Pharm Compd
December 2024
Université de Montréal, Montreal, Quebec, Canada.
Objective: In pediatrics, weight-based doses can be very small, leading to measuring tiny volumes of the commercial desmopressin nasal solution at 0.1mg/mL, which reduces precision and increases the risk of error. Since stability of the desmopressin acetate solution diluted at 0.
View Article and Find Full Text PDFIndian J Nephrol
September 2023
Department of Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Background: The most common complication of percutaneous kidney biopsy is bleeding, which can be seen in up to one-third of cases. The aim of this study was to evaluate the effect of prebiopsy administration of intranasal desmopressin acetate in reducing the incidence of biopsy-related bleeding complications.
Materials And Methods: This was a prospective randomized double-blind pilot study conducted at our center from January 2021 to September 2022.
Neurourol Urodyn
January 2024
Research Center for Evidence-Based Medicine, Iranian EBM Centre: A JBI Centre of Excellence, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Purpose: Evidence on the efficacy of desmopressin in nocturia in patients with neurological diseases is still very limited except for multiple sclerosis (MS). Our aim was to evaluate the efficacy and safety of desmopressin treatment on nocturia in patients with underlying neurological diseases.
Methods: Studies were identified by electronic search of PubMed, Embase, Cochrane, CINAHL, and Google Scholar databases.
Res Pract Thromb Haemost
July 2023
Department of Hematology, Hemophilia Treatment Center, Erasmus MC, Erasmus University Medical Center, Rotterdam, The Netherlands.
Background: Desmopressin increases plasma factor VIII and von Willebrand factor levels in persons with nonsevere hemophilia A. Patients' perspectives on desmopressin are relevant to increase and optimize its suboptimal use. However, patients' views on desmopressin are not reported.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!